Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells | |
Qu, Bingxue1,2; Xu, Yongjin1; Lu, Yang2; Zhuang, Weihao2; Jin, Xinxin2; Shi, Qiuqiu2; Yan, Shike2; Guo, Yu2; Shen, Zheyuan3; Che, Jinxin2,3 | |
刊名 | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY |
2022-05-05 | |
卷号 | 235 |
关键词 | XPO1 Multiple myeloma MM.1S N-phenylsulfonamide Oral administration |
ISSN号 | 0223-5234 |
DOI | 10.1016/j.ejmech.2022.114257 |
通讯作者 | Dong, Xiaowu(dongxw@zju.edu.cn) ; Yang, Haiyan(yanghy@zjcc.org.cn) |
英文摘要 | Multiple myeloma (MM) is a highly malignant hematologic cancer that occurs when an atypical plasma cell develops in the bone marrow and reproduces quickly. Despite varies of new drugs have been developed or under clinic trial, MM is still essentially incurable, while XPO1 inhibition has emerged as a promising therapeutic strategy in the treatment of MM. Using the second-generation XPO1 inhibitor KPT-8602 as the lead compound, structure-based optimization provided D4 with high anti-proliferation efficacy (IC50 =& nbsp;24 nM in MM.1S). In addition, the treatment with D4 significantly induced MM.1S cell cycle arrested and cell apoptosis, which was confirmed as on-target effect by immunofluorescence microscopy and competitive binding assay. Moreover, D4 displayed good metabolic stability over rat plasma and liver microsomes, as well as good pharmacokinetic profile on SD rat model with high drug exposure and decent bioavailability by oral gavage. All these good properties of D4 pave the way for further drug development and clinical application. (C)& nbsp;2022 Elsevier Masson SAS. All rights reserved. |
资助项目 | National Natural Science Foundation of China[82173660] ; National Natural Science Foundation of China[82103975] ; Natural Science Foundation of Zhejiang Province[LR21H300003] ; Natural Science Foundation of Zhejiang Province[LQ21H300005] ; Natural Science Foundation of Zhejiang Province[Q22H302109] |
WOS关键词 | NUCLEAR EXPORT SINE ; SELECTIVE INHIBITORS ; THERAPEUTIC TARGET ; DRUG-METABOLISM ; TRANSPORT |
WOS研究方向 | Pharmacology & Pharmacy |
语种 | 英语 |
出版者 | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER |
WOS记录号 | WOS:000793692700002 |
资助机构 | National Natural Science Foundation of China ; Natural Science Foundation of Zhejiang Province |
内容类型 | 期刊论文 |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/130951] |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Dong, Xiaowu; Yang, Haiyan |
作者单位 | 1.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Univ Chinese Acad Sci, Zhejiang Canc Hosp,Canc Hosp,Dept Lymphoma, Hangzhou, Peoples R China 2.Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou Inst Innovat Med, Inst Drug Discovery & Design, Hangzhou, Peoples R China 3.Zhejiang Univ, Innovat Inst Artificial Intelligence Med, Hangzhou, Peoples R China 4.Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China |
推荐引用方式 GB/T 7714 | Qu, Bingxue,Xu, Yongjin,Lu, Yang,et al. Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,2022,235. |
APA | Qu, Bingxue.,Xu, Yongjin.,Lu, Yang.,Zhuang, Weihao.,Jin, Xinxin.,...&Yang, Haiyan.(2022).Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,235. |
MLA | Qu, Bingxue,et al."Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells".EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 235(2022). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论